Drug delivery systems are a growing sector of the pharmaceutical industry. The backbone of the sector is hinged on research and development into new ways of delivering therapeutic agents for the treatment of cancer and related diseases. A drug delivery system can be either a new and innovative method of administering a drug or a novel twist on an existing drug.

Why is research into cancer drug delivery systems necessary?

Many anti-cancer drugs and therapies are as well known for the associated side effects as their therapeutic benefit. These instantly recognisable side effects can necessitate reduction of dosage of a drug, and can have a serious effect on the well-being of patients. New cancer drug delivery systems are in development to minimise harm to non-cancerous cells, whist enhancing the effect on the tumour itself.

Why buy this report?

Cancer is recognized as the second most common cause of death in the developed world, and can arise as a result of a number of factors. The multifactorial nature of cancer breeds a wealth of potential target genes, enzymes, proteins and hormones. This means that at any one time, there can be more new drugs in development than types of cancer itself. With $26.4 billion invested in the drug industry in 2000, it has established a major market for development and research.

Who should buy this report?

Drug development is inherently risky, and with the potential for failure at any stage of development, it is essential to be well informed. Cancer Drug Delivery Systems by Pharma Reports of visiongain provides an informative insight into the leading companies and technologies in the sector, with an easily understood introduction to cancer at a genetic and cellular level.

Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Related Reports:
Prostate Cancer Drug Discoveries: What the Future Holds
Monoclonal antibodies: 2009 update
Competitor Analysis: TGF-R Agonists and Antagonists
Freedonia Focus on Biologicals
CDK Inhibitors Patent Landscape 2009
Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Pipeline Insight: Colorectal Cancer - Growing trend towards personalized medicine
Stakeholder Insight: Acute Leukemias - Reaching the limits of cytotoxic chemotherapy
Top 20 Cancer Therapy Brands Forecast
Drug Delivery Partnering Agreements in Pharma and Biotech